Pelvic Exenteration in Advanced, Recurrent or Synchronous Cancers-Last Resort or Therapeutic Option?

• Published in: Diagnostics (Basel) 2024-08, Vol.14 (16), p.1707
• Main Authors: Rotaru, Vlad, Chitoran, Elena, Zob, Daniela-Luminita, Ionescu, Sinziana-Octavia, Aisa, Gelal, Andra-Delia, Prie, Serban, Dragos, Stefan, Daniela-Cristina, Simion, Laurentiu
• Format: Article
• Language: English
• Subjects: Cancer; cancer recurrence; Cancer therapies; Care and treatment; Collaboration; Diseases; Health aspects; locally advanced pelvic cancer; Medical prognosis; Methods; Morbidity; Mortality; Oncology; Patient outcomes; Patients; pelvectomy; Pelvic exenteration; Pelvis; Quality of life; radical pelvic surgery; Relapse; Surgeons; Surgery; survival
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14161707

First described some 80 years ago, pelvic exenteration remain controversial interventions with variable results and ever-changing indications. The previous studies are not homogenous and have different inclusion criteria (different populations and different disease characteristics) and methodologies (including evaluation of results), making it extremely difficult to properly assess the role of pelvic exenteration in cancer treatment. This study aims to describe the indications of pelvic exenterations, the main prognostic factors of oncologic results, and the possible complications of the intervention. For this purpose, we conducted a retrospective study of 132 patients who underwent various forms of pelvic exenterations in the Institute of Oncology "Prof. Dr. Al. Trestioreanu" in Bucharest, Romania, between 2013 and 2022, collecting sociodemographic data, characteristics of patients, information on the disease treated, data about the surgical procedure, complications, additional cancer treatments, and oncologic results. The study cohort consists of gynecological, colorectal, and urinary bladder malignancies (one hundred twenty-seven patients) and five patients with complex fistulas between pelvic organs. An R0 resection was possible in 76.38% of cases, while on the rest, positive margins on resection specimens were observed. The early morbidity was 40.63% and the mortality was 2.72%. Long-term outcomes included an overall survival of 43.7 months and a median recurrence-free survival of 24.3 months. The most important determinants of OS are completeness of resection, the colorectal origin of tumor, and the presence/absence of lymphovascular invasion. Although still associated with high morbidity rates, pelvic exenterations can deliver important improvements in oncological outcomes in the long-term and should be considered on a case-by-case basis. A good selection of patients and an experienced surgical team can facilitate optimal risks/benefits.